AZEEM ANJUM: Open Payments
NPI 1114516150 · NATIONAL CITY, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,987 in 121 payments from 12 companies in 2025. Trend: 2023 $399 · 2024 $1,690 · 2025 $2,987
Food & beverage: $2,868Education: $119
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 20 | $527 |
| Teva Pharmaceuticals USA, Inc. | 24 | $386 |
| Janssen Pharmaceuticals, Inc | 15 | $327 |
| Alkermes, Inc. | 6 | $325 |
| Otsuka America Pharmaceutical, Inc. | 13 | $312 |
| Neurocrine BioSciences, Inc. | 13 | $298 |
| ACADIA Pharmaceuticals Inc | 7 | $247 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $224 |
| ABBVIE INC. | 7 | $137 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 3 | $98 |
Products named: COBENFY, INVEGA SUSTENNA, REXULTI, INGREZZA, NUPLAZID, CAPLYTA, ARISTADA, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
